Showing Latest Articles
Type 2 diabetes mellitus and prognosis in early stage breast cancer women
Medical Oncology, 11/17/2011
Kaplan MA et al. – The results suggest that diabetes is an independent prognostic factor for breast cancer.
Methods- The cases included in this retrospective study were selected from breast cancer women who had undergone mastectomy and completed adjuvant chemotherapy from 1998 to 2010.
- Patients were classified into two groups: diabetic and non-diabetic.
- Patients’ age, sex, menopausal status, body mass index (BMI), histopathological features, tumor size, lymph node involvement, hormone receptor and HER2-neu status, and treatment types were recorded.
- There were 483 breast cancer patients included in the study.
- Postmenopausal patients’ rate (53.7% vs. 36.8%, P=0.016) and mean BMI levels were statistically higher (32.2 vs. 27.9, P=0.007) in diabetic patients.
- There was no statistical difference for histological subgroup, grade, ER and PR positivity, HER2-neu overexpression rate, and tumor size between the diabetic and non-diabetic group.
- Lymph node involvements were statistically higher in diabetic patients compared with non-diabetic patients (P=0.013).
- Median disease-free survival is 81months (95% CI, 61.6-100.4) in non-diabetic patients and 36 months (95% CI, 13.6-58.4) in diabetic patients (P<0.001).
- The odds ratio of recurrence was significantly increased in those with HER2-neu overexpression and lymph node involvement and decreased with PR-positive tumors.